Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TDZD-8 (NP 01139) 是抑制GSK-3β的抑制剂,其 IC50=2 μM。它对 Cdk-1/cyclin B,CK-II,PKA 和 PKC 的作用较弱,IC50值均 <100 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 445 | 现货 | ||
10 mg | ¥ 634 | 现货 | ||
25 mg | ¥ 1,163 | 现货 | ||
50 mg | ¥ 1,919 | 现货 | ||
100 mg | ¥ 2,675 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 487 | 现货 |
产品描述 | TDZD-8 (NP 01139) is an inhibitor of GSK-3β, with an IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC. |
靶点活性 | GSK-3β:2 μM |
体外活性 | TDZD-8 acts as a noncompetitive inhibitor of ATP or GS-1 binding. TDZD-8 shows no inhibition of PKA, PKC, Cdk-1/cyclin B or CK-II in kinase assays. [1] TDZD-8 specifically induces cell death of primary leukemia specimens. TDZD-8 ablates leukemia progenitor and stem cells. TDZD-8 treatment induces oxidative stress. TDZD-8 induces cell death with extremely rapid cell death kinetics showing loss of membrane integrity. TDZD-8 inhibits PKC and FLT3 in primary AML specimens. [2] |
别名 | GSK-3β Inhibitor I, NP 01139 |
分子量 | 222.26 |
分子式 | C10H10N2O2S |
CAS No. | 327036-89-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 44.5 mg/mL (200.21 mM)
Ethanol: 44.5 mg/mL (200.21 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 4.4992 mL | 22.4962 mL | 44.9924 mL | 112.4809 mL |
5 mM | 0.8998 mL | 4.4992 mL | 8.9985 mL | 22.4962 mL | |
10 mM | 0.4499 mL | 2.2496 mL | 4.4992 mL | 11.2481 mL | |
20 mM | 0.225 mL | 1.1248 mL | 2.2496 mL | 5.624 mL | |
50 mM | 0.09 mL | 0.4499 mL | 0.8998 mL | 2.2496 mL | |
100 mM | 0.045 mL | 0.225 mL | 0.4499 mL | 1.1248 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TDZD-8 327036-89-5 PI3K/Akt/mTOR signaling Stem Cells GSK-3 inhibit GSK-3β Inhibitor I NP-01139 NP01139 Inhibitor TDZD8 GSK-3beta Inhibitor I NP 01139 TDZD 8 GSK-3b Inhibitor I Glycogen synthase kinase 3 Glycogen synthase kinase-3 inhibitor